Too advanced for assessment? Advanced materials, nanomedicine and the environment
Abstract Advanced materials, and nanomaterials, are promising for healthcare applications and are in particular in the spotlight of medical innovation since rapidly developed nano-formulated vaccines provide relief in the SARS-CoV-2 pandemic. Further increased rapid growth is to be expected as more...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Berkner, Silvia [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2022 |
|---|
| Schlagwörter: |
|---|
| Anmerkung: |
© The Author(s) 2022 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Umweltwissenschaften und Schadstoff-Forschung - Heidelberg : Springer, 1989, 34(2022), 1 vom: 16. Aug. |
|---|---|
| Übergeordnetes Werk: |
volume:34 ; year:2022 ; number:1 ; day:16 ; month:08 |
| Links: |
|---|
| DOI / URN: |
10.1186/s12302-022-00647-7 |
|---|
| Katalog-ID: |
SPR047864737 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR047864737 | ||
| 003 | DE-627 | ||
| 005 | 20230509105832.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220817s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12302-022-00647-7 |2 doi | |
| 035 | |a (DE-627)SPR047864737 | ||
| 035 | |a (SPR)s12302-022-00647-7-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Berkner, Silvia |e verfasserin |0 (orcid)0000-0002-4713-7544 |4 aut | |
| 245 | 1 | 0 | |a Too advanced for assessment? Advanced materials, nanomedicine and the environment |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2022 | ||
| 520 | |a Abstract Advanced materials, and nanomaterials, are promising for healthcare applications and are in particular in the spotlight of medical innovation since rapidly developed nano-formulated vaccines provide relief in the SARS-CoV-2 pandemic. Further increased rapid growth is to be expected as more and more products are in development and reach the market, beneficial for human health. However, the human body is not a dead end and these products are likely to enter the environment, whereas their fate and effects in the environment are unknown. This part of the life-cycle of advanced medicinal products tends to be overlooked, if the perspective is human-centered and excludes the connectedness of human activity with, and consequences for our environment. Gaps are reviewed that exist in awareness, perspective taking, inclusion of environmental concerns into research and product development and also in available methodologies and regulatory guidance. To bridge these gaps, possible ways forward start to emerge, that could help to find a more integrative way of assessing human and environmental safety for advanced material medicinal products and nanomedicines. | ||
| 650 | 4 | |a Nanomedicine |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Medicinal advanced materials |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Nanopharmaceuticals |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Safety assessment |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Environmental impact |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a One Health |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Schwirn, Kathrin |4 aut | |
| 700 | 1 | |a Voelker, Doris |0 (orcid)0000-0003-4589-1997 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Umweltwissenschaften und Schadstoff-Forschung |d Heidelberg : Springer, 1989 |g 34(2022), 1 vom: 16. Aug. |w (DE-627)319337200 |w (DE-600)2014183-X |x 1865-5084 |7 nnns |
| 773 | 1 | 8 | |g volume:34 |g year:2022 |g number:1 |g day:16 |g month:08 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s12302-022-00647-7 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a GBV_ILN_60 | ||
| 912 | |a GBV_ILN_95 | ||
| 912 | |a GBV_ILN_370 | ||
| 912 | |a GBV_ILN_2360 | ||
| 951 | |a AR | ||
| 952 | |d 34 |j 2022 |e 1 |b 16 |c 08 | ||
| author_variant |
s b sb k s ks d v dv |
|---|---|
| matchkey_str |
article:18655084:2022----::oavnefrsesetdacdaeilnnmdc |
| hierarchy_sort_str |
2022 |
| publishDate |
2022 |
| allfields |
10.1186/s12302-022-00647-7 doi (DE-627)SPR047864737 (SPR)s12302-022-00647-7-e DE-627 ger DE-627 rakwb eng Berkner, Silvia verfasserin (orcid)0000-0002-4713-7544 aut Too advanced for assessment? Advanced materials, nanomedicine and the environment 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2022 Abstract Advanced materials, and nanomaterials, are promising for healthcare applications and are in particular in the spotlight of medical innovation since rapidly developed nano-formulated vaccines provide relief in the SARS-CoV-2 pandemic. Further increased rapid growth is to be expected as more and more products are in development and reach the market, beneficial for human health. However, the human body is not a dead end and these products are likely to enter the environment, whereas their fate and effects in the environment are unknown. This part of the life-cycle of advanced medicinal products tends to be overlooked, if the perspective is human-centered and excludes the connectedness of human activity with, and consequences for our environment. Gaps are reviewed that exist in awareness, perspective taking, inclusion of environmental concerns into research and product development and also in available methodologies and regulatory guidance. To bridge these gaps, possible ways forward start to emerge, that could help to find a more integrative way of assessing human and environmental safety for advanced material medicinal products and nanomedicines. Nanomedicine (dpeaa)DE-He213 Medicinal advanced materials (dpeaa)DE-He213 Nanopharmaceuticals (dpeaa)DE-He213 Safety assessment (dpeaa)DE-He213 Environmental impact (dpeaa)DE-He213 One Health (dpeaa)DE-He213 Schwirn, Kathrin aut Voelker, Doris (orcid)0000-0003-4589-1997 aut Enthalten in Umweltwissenschaften und Schadstoff-Forschung Heidelberg : Springer, 1989 34(2022), 1 vom: 16. Aug. (DE-627)319337200 (DE-600)2014183-X 1865-5084 nnns volume:34 year:2022 number:1 day:16 month:08 https://dx.doi.org/10.1186/s12302-022-00647-7 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_60 GBV_ILN_95 GBV_ILN_370 GBV_ILN_2360 AR 34 2022 1 16 08 |
| spelling |
10.1186/s12302-022-00647-7 doi (DE-627)SPR047864737 (SPR)s12302-022-00647-7-e DE-627 ger DE-627 rakwb eng Berkner, Silvia verfasserin (orcid)0000-0002-4713-7544 aut Too advanced for assessment? Advanced materials, nanomedicine and the environment 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2022 Abstract Advanced materials, and nanomaterials, are promising for healthcare applications and are in particular in the spotlight of medical innovation since rapidly developed nano-formulated vaccines provide relief in the SARS-CoV-2 pandemic. Further increased rapid growth is to be expected as more and more products are in development and reach the market, beneficial for human health. However, the human body is not a dead end and these products are likely to enter the environment, whereas their fate and effects in the environment are unknown. This part of the life-cycle of advanced medicinal products tends to be overlooked, if the perspective is human-centered and excludes the connectedness of human activity with, and consequences for our environment. Gaps are reviewed that exist in awareness, perspective taking, inclusion of environmental concerns into research and product development and also in available methodologies and regulatory guidance. To bridge these gaps, possible ways forward start to emerge, that could help to find a more integrative way of assessing human and environmental safety for advanced material medicinal products and nanomedicines. Nanomedicine (dpeaa)DE-He213 Medicinal advanced materials (dpeaa)DE-He213 Nanopharmaceuticals (dpeaa)DE-He213 Safety assessment (dpeaa)DE-He213 Environmental impact (dpeaa)DE-He213 One Health (dpeaa)DE-He213 Schwirn, Kathrin aut Voelker, Doris (orcid)0000-0003-4589-1997 aut Enthalten in Umweltwissenschaften und Schadstoff-Forschung Heidelberg : Springer, 1989 34(2022), 1 vom: 16. Aug. (DE-627)319337200 (DE-600)2014183-X 1865-5084 nnns volume:34 year:2022 number:1 day:16 month:08 https://dx.doi.org/10.1186/s12302-022-00647-7 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_60 GBV_ILN_95 GBV_ILN_370 GBV_ILN_2360 AR 34 2022 1 16 08 |
| allfields_unstemmed |
10.1186/s12302-022-00647-7 doi (DE-627)SPR047864737 (SPR)s12302-022-00647-7-e DE-627 ger DE-627 rakwb eng Berkner, Silvia verfasserin (orcid)0000-0002-4713-7544 aut Too advanced for assessment? Advanced materials, nanomedicine and the environment 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2022 Abstract Advanced materials, and nanomaterials, are promising for healthcare applications and are in particular in the spotlight of medical innovation since rapidly developed nano-formulated vaccines provide relief in the SARS-CoV-2 pandemic. Further increased rapid growth is to be expected as more and more products are in development and reach the market, beneficial for human health. However, the human body is not a dead end and these products are likely to enter the environment, whereas their fate and effects in the environment are unknown. This part of the life-cycle of advanced medicinal products tends to be overlooked, if the perspective is human-centered and excludes the connectedness of human activity with, and consequences for our environment. Gaps are reviewed that exist in awareness, perspective taking, inclusion of environmental concerns into research and product development and also in available methodologies and regulatory guidance. To bridge these gaps, possible ways forward start to emerge, that could help to find a more integrative way of assessing human and environmental safety for advanced material medicinal products and nanomedicines. Nanomedicine (dpeaa)DE-He213 Medicinal advanced materials (dpeaa)DE-He213 Nanopharmaceuticals (dpeaa)DE-He213 Safety assessment (dpeaa)DE-He213 Environmental impact (dpeaa)DE-He213 One Health (dpeaa)DE-He213 Schwirn, Kathrin aut Voelker, Doris (orcid)0000-0003-4589-1997 aut Enthalten in Umweltwissenschaften und Schadstoff-Forschung Heidelberg : Springer, 1989 34(2022), 1 vom: 16. Aug. (DE-627)319337200 (DE-600)2014183-X 1865-5084 nnns volume:34 year:2022 number:1 day:16 month:08 https://dx.doi.org/10.1186/s12302-022-00647-7 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_60 GBV_ILN_95 GBV_ILN_370 GBV_ILN_2360 AR 34 2022 1 16 08 |
| allfieldsGer |
10.1186/s12302-022-00647-7 doi (DE-627)SPR047864737 (SPR)s12302-022-00647-7-e DE-627 ger DE-627 rakwb eng Berkner, Silvia verfasserin (orcid)0000-0002-4713-7544 aut Too advanced for assessment? Advanced materials, nanomedicine and the environment 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2022 Abstract Advanced materials, and nanomaterials, are promising for healthcare applications and are in particular in the spotlight of medical innovation since rapidly developed nano-formulated vaccines provide relief in the SARS-CoV-2 pandemic. Further increased rapid growth is to be expected as more and more products are in development and reach the market, beneficial for human health. However, the human body is not a dead end and these products are likely to enter the environment, whereas their fate and effects in the environment are unknown. This part of the life-cycle of advanced medicinal products tends to be overlooked, if the perspective is human-centered and excludes the connectedness of human activity with, and consequences for our environment. Gaps are reviewed that exist in awareness, perspective taking, inclusion of environmental concerns into research and product development and also in available methodologies and regulatory guidance. To bridge these gaps, possible ways forward start to emerge, that could help to find a more integrative way of assessing human and environmental safety for advanced material medicinal products and nanomedicines. Nanomedicine (dpeaa)DE-He213 Medicinal advanced materials (dpeaa)DE-He213 Nanopharmaceuticals (dpeaa)DE-He213 Safety assessment (dpeaa)DE-He213 Environmental impact (dpeaa)DE-He213 One Health (dpeaa)DE-He213 Schwirn, Kathrin aut Voelker, Doris (orcid)0000-0003-4589-1997 aut Enthalten in Umweltwissenschaften und Schadstoff-Forschung Heidelberg : Springer, 1989 34(2022), 1 vom: 16. Aug. (DE-627)319337200 (DE-600)2014183-X 1865-5084 nnns volume:34 year:2022 number:1 day:16 month:08 https://dx.doi.org/10.1186/s12302-022-00647-7 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_60 GBV_ILN_95 GBV_ILN_370 GBV_ILN_2360 AR 34 2022 1 16 08 |
| allfieldsSound |
10.1186/s12302-022-00647-7 doi (DE-627)SPR047864737 (SPR)s12302-022-00647-7-e DE-627 ger DE-627 rakwb eng Berkner, Silvia verfasserin (orcid)0000-0002-4713-7544 aut Too advanced for assessment? Advanced materials, nanomedicine and the environment 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2022 Abstract Advanced materials, and nanomaterials, are promising for healthcare applications and are in particular in the spotlight of medical innovation since rapidly developed nano-formulated vaccines provide relief in the SARS-CoV-2 pandemic. Further increased rapid growth is to be expected as more and more products are in development and reach the market, beneficial for human health. However, the human body is not a dead end and these products are likely to enter the environment, whereas their fate and effects in the environment are unknown. This part of the life-cycle of advanced medicinal products tends to be overlooked, if the perspective is human-centered and excludes the connectedness of human activity with, and consequences for our environment. Gaps are reviewed that exist in awareness, perspective taking, inclusion of environmental concerns into research and product development and also in available methodologies and regulatory guidance. To bridge these gaps, possible ways forward start to emerge, that could help to find a more integrative way of assessing human and environmental safety for advanced material medicinal products and nanomedicines. Nanomedicine (dpeaa)DE-He213 Medicinal advanced materials (dpeaa)DE-He213 Nanopharmaceuticals (dpeaa)DE-He213 Safety assessment (dpeaa)DE-He213 Environmental impact (dpeaa)DE-He213 One Health (dpeaa)DE-He213 Schwirn, Kathrin aut Voelker, Doris (orcid)0000-0003-4589-1997 aut Enthalten in Umweltwissenschaften und Schadstoff-Forschung Heidelberg : Springer, 1989 34(2022), 1 vom: 16. Aug. (DE-627)319337200 (DE-600)2014183-X 1865-5084 nnns volume:34 year:2022 number:1 day:16 month:08 https://dx.doi.org/10.1186/s12302-022-00647-7 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_60 GBV_ILN_95 GBV_ILN_370 GBV_ILN_2360 AR 34 2022 1 16 08 |
| language |
English |
| source |
Enthalten in Umweltwissenschaften und Schadstoff-Forschung 34(2022), 1 vom: 16. Aug. volume:34 year:2022 number:1 day:16 month:08 |
| sourceStr |
Enthalten in Umweltwissenschaften und Schadstoff-Forschung 34(2022), 1 vom: 16. Aug. volume:34 year:2022 number:1 day:16 month:08 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Nanomedicine Medicinal advanced materials Nanopharmaceuticals Safety assessment Environmental impact One Health |
| isfreeaccess_bool |
true |
| container_title |
Umweltwissenschaften und Schadstoff-Forschung |
| authorswithroles_txt_mv |
Berkner, Silvia @@aut@@ Schwirn, Kathrin @@aut@@ Voelker, Doris @@aut@@ |
| publishDateDaySort_date |
2022-08-16T00:00:00Z |
| hierarchy_top_id |
319337200 |
| id |
SPR047864737 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR047864737</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230509105832.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220817s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/s12302-022-00647-7</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR047864737</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s12302-022-00647-7-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Berkner, Silvia</subfield><subfield code="e">verfasserin</subfield><subfield code="0">(orcid)0000-0002-4713-7544</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Too advanced for assessment? Advanced materials, nanomedicine and the environment</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© The Author(s) 2022</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Advanced materials, and nanomaterials, are promising for healthcare applications and are in particular in the spotlight of medical innovation since rapidly developed nano-formulated vaccines provide relief in the SARS-CoV-2 pandemic. Further increased rapid growth is to be expected as more and more products are in development and reach the market, beneficial for human health. However, the human body is not a dead end and these products are likely to enter the environment, whereas their fate and effects in the environment are unknown. This part of the life-cycle of advanced medicinal products tends to be overlooked, if the perspective is human-centered and excludes the connectedness of human activity with, and consequences for our environment. Gaps are reviewed that exist in awareness, perspective taking, inclusion of environmental concerns into research and product development and also in available methodologies and regulatory guidance. To bridge these gaps, possible ways forward start to emerge, that could help to find a more integrative way of assessing human and environmental safety for advanced material medicinal products and nanomedicines.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Nanomedicine</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medicinal advanced materials</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Nanopharmaceuticals</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Safety assessment</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Environmental impact</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">One Health</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schwirn, Kathrin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Voelker, Doris</subfield><subfield code="0">(orcid)0000-0003-4589-1997</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Umweltwissenschaften und Schadstoff-Forschung</subfield><subfield code="d">Heidelberg : Springer, 1989</subfield><subfield code="g">34(2022), 1 vom: 16. Aug.</subfield><subfield code="w">(DE-627)319337200</subfield><subfield code="w">(DE-600)2014183-X</subfield><subfield code="x">1865-5084</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:34</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:1</subfield><subfield code="g">day:16</subfield><subfield code="g">month:08</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1186/s12302-022-00647-7</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2360</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">34</subfield><subfield code="j">2022</subfield><subfield code="e">1</subfield><subfield code="b">16</subfield><subfield code="c">08</subfield></datafield></record></collection>
|
| author |
Berkner, Silvia |
| spellingShingle |
Berkner, Silvia misc Nanomedicine misc Medicinal advanced materials misc Nanopharmaceuticals misc Safety assessment misc Environmental impact misc One Health Too advanced for assessment? Advanced materials, nanomedicine and the environment |
| authorStr |
Berkner, Silvia |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)319337200 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1865-5084 |
| topic_title |
Too advanced for assessment? Advanced materials, nanomedicine and the environment Nanomedicine (dpeaa)DE-He213 Medicinal advanced materials (dpeaa)DE-He213 Nanopharmaceuticals (dpeaa)DE-He213 Safety assessment (dpeaa)DE-He213 Environmental impact (dpeaa)DE-He213 One Health (dpeaa)DE-He213 |
| topic |
misc Nanomedicine misc Medicinal advanced materials misc Nanopharmaceuticals misc Safety assessment misc Environmental impact misc One Health |
| topic_unstemmed |
misc Nanomedicine misc Medicinal advanced materials misc Nanopharmaceuticals misc Safety assessment misc Environmental impact misc One Health |
| topic_browse |
misc Nanomedicine misc Medicinal advanced materials misc Nanopharmaceuticals misc Safety assessment misc Environmental impact misc One Health |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Umweltwissenschaften und Schadstoff-Forschung |
| hierarchy_parent_id |
319337200 |
| hierarchy_top_title |
Umweltwissenschaften und Schadstoff-Forschung |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)319337200 (DE-600)2014183-X |
| title |
Too advanced for assessment? Advanced materials, nanomedicine and the environment |
| ctrlnum |
(DE-627)SPR047864737 (SPR)s12302-022-00647-7-e |
| title_full |
Too advanced for assessment? Advanced materials, nanomedicine and the environment |
| author_sort |
Berkner, Silvia |
| journal |
Umweltwissenschaften und Schadstoff-Forschung |
| journalStr |
Umweltwissenschaften und Schadstoff-Forschung |
| lang_code |
eng |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2022 |
| contenttype_str_mv |
txt |
| author_browse |
Berkner, Silvia Schwirn, Kathrin Voelker, Doris |
| container_volume |
34 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Berkner, Silvia |
| doi_str_mv |
10.1186/s12302-022-00647-7 |
| normlink |
(ORCID)0000-0002-4713-7544 (ORCID)0000-0003-4589-1997 |
| normlink_prefix_str_mv |
(orcid)0000-0002-4713-7544 (orcid)0000-0003-4589-1997 |
| title_sort |
too advanced for assessment? advanced materials, nanomedicine and the environment |
| title_auth |
Too advanced for assessment? Advanced materials, nanomedicine and the environment |
| abstract |
Abstract Advanced materials, and nanomaterials, are promising for healthcare applications and are in particular in the spotlight of medical innovation since rapidly developed nano-formulated vaccines provide relief in the SARS-CoV-2 pandemic. Further increased rapid growth is to be expected as more and more products are in development and reach the market, beneficial for human health. However, the human body is not a dead end and these products are likely to enter the environment, whereas their fate and effects in the environment are unknown. This part of the life-cycle of advanced medicinal products tends to be overlooked, if the perspective is human-centered and excludes the connectedness of human activity with, and consequences for our environment. Gaps are reviewed that exist in awareness, perspective taking, inclusion of environmental concerns into research and product development and also in available methodologies and regulatory guidance. To bridge these gaps, possible ways forward start to emerge, that could help to find a more integrative way of assessing human and environmental safety for advanced material medicinal products and nanomedicines. © The Author(s) 2022 |
| abstractGer |
Abstract Advanced materials, and nanomaterials, are promising for healthcare applications and are in particular in the spotlight of medical innovation since rapidly developed nano-formulated vaccines provide relief in the SARS-CoV-2 pandemic. Further increased rapid growth is to be expected as more and more products are in development and reach the market, beneficial for human health. However, the human body is not a dead end and these products are likely to enter the environment, whereas their fate and effects in the environment are unknown. This part of the life-cycle of advanced medicinal products tends to be overlooked, if the perspective is human-centered and excludes the connectedness of human activity with, and consequences for our environment. Gaps are reviewed that exist in awareness, perspective taking, inclusion of environmental concerns into research and product development and also in available methodologies and regulatory guidance. To bridge these gaps, possible ways forward start to emerge, that could help to find a more integrative way of assessing human and environmental safety for advanced material medicinal products and nanomedicines. © The Author(s) 2022 |
| abstract_unstemmed |
Abstract Advanced materials, and nanomaterials, are promising for healthcare applications and are in particular in the spotlight of medical innovation since rapidly developed nano-formulated vaccines provide relief in the SARS-CoV-2 pandemic. Further increased rapid growth is to be expected as more and more products are in development and reach the market, beneficial for human health. However, the human body is not a dead end and these products are likely to enter the environment, whereas their fate and effects in the environment are unknown. This part of the life-cycle of advanced medicinal products tends to be overlooked, if the perspective is human-centered and excludes the connectedness of human activity with, and consequences for our environment. Gaps are reviewed that exist in awareness, perspective taking, inclusion of environmental concerns into research and product development and also in available methodologies and regulatory guidance. To bridge these gaps, possible ways forward start to emerge, that could help to find a more integrative way of assessing human and environmental safety for advanced material medicinal products and nanomedicines. © The Author(s) 2022 |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_60 GBV_ILN_95 GBV_ILN_370 GBV_ILN_2360 |
| container_issue |
1 |
| title_short |
Too advanced for assessment? Advanced materials, nanomedicine and the environment |
| url |
https://dx.doi.org/10.1186/s12302-022-00647-7 |
| remote_bool |
true |
| author2 |
Schwirn, Kathrin Voelker, Doris |
| author2Str |
Schwirn, Kathrin Voelker, Doris |
| ppnlink |
319337200 |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.1186/s12302-022-00647-7 |
| up_date |
2024-07-03T15:29:56.794Z |
| _version_ |
1803572317308059648 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR047864737</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230509105832.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220817s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/s12302-022-00647-7</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR047864737</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s12302-022-00647-7-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Berkner, Silvia</subfield><subfield code="e">verfasserin</subfield><subfield code="0">(orcid)0000-0002-4713-7544</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Too advanced for assessment? Advanced materials, nanomedicine and the environment</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© The Author(s) 2022</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Advanced materials, and nanomaterials, are promising for healthcare applications and are in particular in the spotlight of medical innovation since rapidly developed nano-formulated vaccines provide relief in the SARS-CoV-2 pandemic. Further increased rapid growth is to be expected as more and more products are in development and reach the market, beneficial for human health. However, the human body is not a dead end and these products are likely to enter the environment, whereas their fate and effects in the environment are unknown. This part of the life-cycle of advanced medicinal products tends to be overlooked, if the perspective is human-centered and excludes the connectedness of human activity with, and consequences for our environment. Gaps are reviewed that exist in awareness, perspective taking, inclusion of environmental concerns into research and product development and also in available methodologies and regulatory guidance. To bridge these gaps, possible ways forward start to emerge, that could help to find a more integrative way of assessing human and environmental safety for advanced material medicinal products and nanomedicines.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Nanomedicine</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medicinal advanced materials</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Nanopharmaceuticals</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Safety assessment</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Environmental impact</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">One Health</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schwirn, Kathrin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Voelker, Doris</subfield><subfield code="0">(orcid)0000-0003-4589-1997</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Umweltwissenschaften und Schadstoff-Forschung</subfield><subfield code="d">Heidelberg : Springer, 1989</subfield><subfield code="g">34(2022), 1 vom: 16. Aug.</subfield><subfield code="w">(DE-627)319337200</subfield><subfield code="w">(DE-600)2014183-X</subfield><subfield code="x">1865-5084</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:34</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:1</subfield><subfield code="g">day:16</subfield><subfield code="g">month:08</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1186/s12302-022-00647-7</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2360</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">34</subfield><subfield code="j">2022</subfield><subfield code="e">1</subfield><subfield code="b">16</subfield><subfield code="c">08</subfield></datafield></record></collection>
|
| score |
7.401124 |